NZ507426A - Compounds, screening methods, and uses involving anti-apoptotic genes and gene products - Google Patents

Info

Publication number

NZ507426A

NZ507426A NZ507426A NZ50742699A NZ507426A NZ 507426 A NZ507426 A NZ 507426A NZ 507426 A NZ507426 A NZ 507426A NZ 50742699 A NZ50742699 A NZ 50742699A NZ 507426 A NZ507426 A NZ 507426A

Authority

NZ

New Zealand

Prior art keywords

polypeptide

cells

apoptotic activity

compound

polypeptides

Prior art date

1998-05-18

Links

• Espacenet
• Global Dossier
• Discuss

• 230000002424 anti-apoptotic effect Effects 0.000 title claims abstract description 357
• 150000001875 compounds Chemical class 0.000 title claims abstract description 301
• 238000000034 method Methods 0.000 title claims abstract description 248
• 238000012216 screening Methods 0.000 title claims abstract description 74
• 108090000623 proteins and genes Proteins 0.000 title claims description 48
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 862
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 839
• 229920001184 polypeptide Polymers 0.000 claims abstract description 831
• 102000040430 polynucleotide Human genes 0.000 claims abstract description 242
• 108091033319 polynucleotide Proteins 0.000 claims abstract description 242
• 239000002157 polynucleotide Substances 0.000 claims abstract description 242
• 230000006907 apoptotic process Effects 0.000 claims abstract description 144
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 78
• 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 24
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
• 230000012010 growth Effects 0.000 claims abstract description 10
• 230000002708 enhancing effect Effects 0.000 claims abstract description 7
• 210000004027 cell Anatomy 0.000 claims description 397
• 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 191
• 230000003612 virological effect Effects 0.000 claims description 130
• 230000014509 gene expression Effects 0.000 claims description 66
• 125000003729 nucleotide group Chemical group 0.000 claims description 64
• 239000012634 fragment Substances 0.000 claims description 63
• 230000001640 apoptogenic effect Effects 0.000 claims description 60
• 235000011468 Albizia julibrissin Nutrition 0.000 claims description 58
• 241001070944 Mimosa Species 0.000 claims description 58
• 238000009739 binding Methods 0.000 claims description 55
• 150000001413 amino acids Chemical class 0.000 claims description 52
• 230000027455 binding Effects 0.000 claims description 51
• 239000002773 nucleotide Substances 0.000 claims description 47
• 238000003556 assay Methods 0.000 claims description 44
• 102000004091 Caspase-8 Human genes 0.000 claims description 39
• 108090000538 Caspase-8 Proteins 0.000 claims description 39
• 208000035475 disorder Diseases 0.000 claims description 35
• 102100026693 FAS-associated death domain protein Human genes 0.000 claims description 34
• 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 claims description 34
• 108090000397 Caspase 3 Proteins 0.000 claims description 33
• 102100029855 Caspase-3 Human genes 0.000 claims description 33
• 239000003795 chemical substances by application Substances 0.000 claims description 31
• 101150085237 UL36 gene Proteins 0.000 claims description 30
• 230000030833 cell death Effects 0.000 claims description 29
• 230000002401 inhibitory effect Effects 0.000 claims description 29
• 108091034117 Oligonucleotide Proteins 0.000 claims description 28
• 238000000338 in vitro Methods 0.000 claims description 28
• 241000282414 Homo sapiens Species 0.000 claims description 27
• 230000003467 diminishing effect Effects 0.000 claims description 27
• 230000001939 inductive effect Effects 0.000 claims description 27
• 239000000126 substance Substances 0.000 claims description 27
• 230000003412 degenerative effect Effects 0.000 claims description 26
• 230000009870 specific binding Effects 0.000 claims description 26
• 238000000159 protein binding assay Methods 0.000 claims description 23
• 210000001519 tissue Anatomy 0.000 claims description 23
• 230000001413 cellular effect Effects 0.000 claims description 22
• 210000005260 human cell Anatomy 0.000 claims description 22
• 239000003814 drug Substances 0.000 claims description 21
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 18
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 18
• 206010028980 Neoplasm Diseases 0.000 claims description 18
• 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 18
• 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 18
• 230000001594 aberrant effect Effects 0.000 claims description 18
• 239000000074 antisense oligonucleotide Substances 0.000 claims description 17
• 238000012230 antisense oligonucleotides Methods 0.000 claims description 17
• 238000001727 in vivo Methods 0.000 claims description 17
• 239000000203 mixture Substances 0.000 claims description 17
• 101150064015 FAS gene Proteins 0.000 claims description 15
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 15
• 238000004519 manufacturing process Methods 0.000 claims description 15
• 201000011510 cancer Diseases 0.000 claims description 14
• 230000001404 mediated effect Effects 0.000 claims description 14
• 230000004663 cell proliferation Effects 0.000 claims description 12
• 210000002950 fibroblast Anatomy 0.000 claims description 12
• 238000001890 transfection Methods 0.000 claims description 12
• -1 Apaf-1 Proteins 0.000 claims description 9
• 208000023275 Autoimmune disease Diseases 0.000 claims description 9
• 230000004913 activation Effects 0.000 claims description 9
• 230000000295 complement effect Effects 0.000 claims description 9
• 108010052621 fas Receptor Proteins 0.000 claims description 9
• 102000018823 fas Receptor Human genes 0.000 claims description 9
• 208000015181 infectious disease Diseases 0.000 claims description 9
• 239000002502 liposome Substances 0.000 claims description 9
• 210000004698 lymphocyte Anatomy 0.000 claims description 9
• 230000005764 inhibitory process Effects 0.000 claims description 8
• 230000009466 transformation Effects 0.000 claims description 8
• 208000036142 Viral infection Diseases 0.000 claims description 7
• 210000004408 hybridoma Anatomy 0.000 claims description 7
• 230000019491 signal transduction Effects 0.000 claims description 7
• 230000009385 viral infection Effects 0.000 claims description 7
• 239000013603 viral vector Substances 0.000 claims description 7
• 102000004039 Caspase-9 Human genes 0.000 claims description 6
• 108090000566 Caspase-9 Proteins 0.000 claims description 6
• 230000033228 biological regulation Effects 0.000 claims description 6
• 102000005962 receptors Human genes 0.000 claims description 6
• 108020003175 receptors Proteins 0.000 claims description 6
• 208000005074 Retroviridae Infections Diseases 0.000 claims description 5
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 5
• 210000003169 central nervous system Anatomy 0.000 claims description 5
• 102100030497 Cytochrome c Human genes 0.000 claims description 4
• 108010075031 Cytochromes c Proteins 0.000 claims description 4
• 206010061216 Infarction Diseases 0.000 claims description 4
• 230000006698 induction Effects 0.000 claims description 4
• 230000007574 infarction Effects 0.000 claims description 4
• 210000003470 mitochondria Anatomy 0.000 claims description 4
• 241000701161 unidentified adenovirus Species 0.000 claims description 4
• 241001430294 unidentified retrovirus Species 0.000 claims description 4
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
• 208000035473 Communicable disease Diseases 0.000 claims description 3
• 241000702421 Dependoparvovirus Species 0.000 claims description 3
• 210000004524 haematopoietic cell Anatomy 0.000 claims description 3
• 208000026278 immune system disease Diseases 0.000 claims description 3
• 230000001613 neoplastic effect Effects 0.000 claims description 3
• 230000001537 neural effect Effects 0.000 claims description 3
• 241000701447 unidentified baculovirus Species 0.000 claims description 3
• 241000700584 Simplexvirus Species 0.000 claims description 2
• 241000700618 Vaccinia virus Species 0.000 claims description 2
• 208000010125 myocardial infarction Diseases 0.000 claims description 2
• 230000002463 transducing effect Effects 0.000 claims description 2
• 230000003292 diminished effect Effects 0.000 claims 5
• 102000046016 B-Cell CLL-Lymphoma 10 Human genes 0.000 claims 1
• 101710109862 B-cell lymphoma/leukemia 10 Proteins 0.000 claims 1
• 108010052832 Cytochromes Proteins 0.000 claims 1
• 102000018832 Cytochromes Human genes 0.000 claims 1
• 102000018594 Tumour necrosis factor Human genes 0.000 claims 1
• 108050007852 Tumour necrosis factor Proteins 0.000 claims 1
• 238000012258 culturing Methods 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 abstract description 64
• 201000010099 disease Diseases 0.000 abstract description 43
• 238000011282 treatment Methods 0.000 abstract description 29
• YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 68
• 108020004414 DNA Proteins 0.000 description 65
• 235000001014 amino acid Nutrition 0.000 description 48
• 229940024606 amino acid Drugs 0.000 description 47
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 44
• 230000000840 anti-viral effect Effects 0.000 description 41
• 239000002299 complementary DNA Substances 0.000 description 31
• 239000013598 vector Substances 0.000 description 29
• 102000055102 bcl-2-Associated X Human genes 0.000 description 28
• 108700000707 bcl-2-Associated X Proteins 0.000 description 28
• 239000000523 sample Substances 0.000 description 28
• 230000000694 effects Effects 0.000 description 23
• 230000003993 interaction Effects 0.000 description 20
• 238000012360 testing method Methods 0.000 description 20
• 238000001262 western blot Methods 0.000 description 19
• 230000006870 function Effects 0.000 description 18
• 239000013612 plasmid Substances 0.000 description 18
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
• 102100040247 Tumor necrosis factor Human genes 0.000 description 17
• 230000004048 modification Effects 0.000 description 17
• 238000012986 modification Methods 0.000 description 17
• 238000010353 genetic engineering Methods 0.000 description 15
• 238000009396 hybridization Methods 0.000 description 15
• 238000003752 polymerase chain reaction Methods 0.000 description 15
• 230000004927 fusion Effects 0.000 description 14
• 239000000047 product Substances 0.000 description 14
• 238000002965 ELISA Methods 0.000 description 13
• 101150036065 UL37 gene Proteins 0.000 description 13
• 230000000692 anti-sense effect Effects 0.000 description 13
• 230000000875 corresponding effect Effects 0.000 description 13
• 238000001514 detection method Methods 0.000 description 13
• 241000894007 species Species 0.000 description 13
• 239000003153 chemical reaction reagent Substances 0.000 description 12
• 229940079593 drug Drugs 0.000 description 12
• 239000013613 expression plasmid Substances 0.000 description 12
• 238000002955 isolation Methods 0.000 description 12
• 238000006467 substitution reaction Methods 0.000 description 12
• 108700026244 Open Reading Frames Proteins 0.000 description 11
• 238000012217 deletion Methods 0.000 description 11
• 230000037430 deletion Effects 0.000 description 11
• 239000003550 marker Substances 0.000 description 11
• 108020004999 messenger RNA Proteins 0.000 description 11
• 102000004169 proteins and genes Human genes 0.000 description 11
• 238000010561 standard procedure Methods 0.000 description 11
• 238000006243 chemical reaction Methods 0.000 description 10
• 235000018102 proteins Nutrition 0.000 description 10
• 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 9
• 206010011831 Cytomegalovirus infection Diseases 0.000 description 9
• 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 8
• 241001465754 Metazoa Species 0.000 description 8
• 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 8
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
• 238000007792 addition Methods 0.000 description 8
• 238000009510 drug design Methods 0.000 description 8
• 239000000284 extract Substances 0.000 description 8
• 239000000499 gel Substances 0.000 description 8
• 230000006882 induction of apoptosis Effects 0.000 description 8
• 230000002452 interceptive effect Effects 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 239000000816 peptidomimetic Substances 0.000 description 8
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
• 102100039556 Galectin-4 Human genes 0.000 description 7
• 108700008625 Reporter Genes Proteins 0.000 description 7
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 241000700605 Viruses Species 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 238000013459 approach Methods 0.000 description 7
• 238000005516 engineering process Methods 0.000 description 7
• 239000013604 expression vector Substances 0.000 description 7
• 238000002372 labelling Methods 0.000 description 7
• 230000007246 mechanism Effects 0.000 description 7
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 230000004962 physiological condition Effects 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 102000011727 Caspases Human genes 0.000 description 6
• 108010076667 Caspases Proteins 0.000 description 6
• 108700024394 Exon Proteins 0.000 description 6
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 6
• 210000001744 T-lymphocyte Anatomy 0.000 description 6
• 210000003719 b-lymphocyte Anatomy 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 239000002981 blocking agent Substances 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 239000000833 heterodimer Substances 0.000 description 6
• 230000002163 immunogen Effects 0.000 description 6
• 238000010369 molecular cloning Methods 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 241001529453 unidentified herpesvirus Species 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 5
• 208000030507 AIDS Diseases 0.000 description 5
• 230000004568 DNA-binding Effects 0.000 description 5
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 5
• 101710110377 Immediate early protein IE1 Proteins 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 210000000170 cell membrane Anatomy 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• 230000018109 developmental process Effects 0.000 description 5
• 238000001415 gene therapy Methods 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 230000000144 pharmacologic effect Effects 0.000 description 5
• 229920002401 polyacrylamide Polymers 0.000 description 5
• 238000007423 screening assay Methods 0.000 description 5
• 235000002639 sodium chloride Nutrition 0.000 description 5
• 238000012289 standard assay Methods 0.000 description 5
• 241001515965 unidentified phage Species 0.000 description 5
• 230000029812 viral genome replication Effects 0.000 description 5
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 208000031886 HIV Infections Diseases 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 241000725303 Human immunodeficiency virus Species 0.000 description 4
• 206010061598 Immunodeficiency Diseases 0.000 description 4
• 108010011942 LH Receptors Proteins 0.000 description 4
• 102000023108 LH Receptors Human genes 0.000 description 4
• 108010038807 Oligopeptides Proteins 0.000 description 4
• 102000015636 Oligopeptides Human genes 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 206010069351 acute lung injury Diseases 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 230000009878 intermolecular interaction Effects 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 150000007523 nucleic acids Chemical class 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 229950010131 puromycin Drugs 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 230000001177 retroviral effect Effects 0.000 description 4
• 238000012163 sequencing technique Methods 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 230000004083 survival effect Effects 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 238000011191 terminal modification Methods 0.000 description 4
• 108091006106 transcriptional activators Proteins 0.000 description 4
• 238000013519 translation Methods 0.000 description 4
• 229920000936 Agarose Polymers 0.000 description 3
• 108090000672 Annexin A5 Proteins 0.000 description 3
• 102000004121 Annexin A5 Human genes 0.000 description 3
• 108090001008 Avidin Proteins 0.000 description 3
• 201000009030 Carcinoma Diseases 0.000 description 3
• 108091035707 Consensus sequence Proteins 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 241000283973 Oryctolagus cuniculus Species 0.000 description 3
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 108010067390 Viral Proteins Proteins 0.000 description 3
• 108020000999 Viral RNA Proteins 0.000 description 3
• 230000005856 abnormality Effects 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 238000003782 apoptosis assay Methods 0.000 description 3
• 230000005775 apoptotic pathway Effects 0.000 description 3
• 108700000711 bcl-X Proteins 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 239000000872 buffer Chemical group 0.000 description 3
• 210000004899 c-terminal region Anatomy 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 230000002860 competitive effect Effects 0.000 description 3
• 230000009918 complex formation Effects 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 239000003599 detergent Substances 0.000 description 3
• 238000002405 diagnostic procedure Methods 0.000 description 3
• 230000008030 elimination Effects 0.000 description 3
• 238000003379 elimination reaction Methods 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 210000003754 fetus Anatomy 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 201000006747 infectious mononucleosis Diseases 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 101150066555 lacZ gene Proteins 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
• 230000009871 nonspecific binding Effects 0.000 description 3
• 230000002028 premature Effects 0.000 description 3
• 238000002360 preparation method Methods 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 230000005522 programmed cell death Effects 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 238000013518 transcription Methods 0.000 description 3
• 230000035897 transcription Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000001960 triggered effect Effects 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• 210000005253 yeast cell Anatomy 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108020004491 Antisense DNA Proteins 0.000 description 2
• 108020005544 Antisense RNA Proteins 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• 102000051485 Bcl-2 family Human genes 0.000 description 2
• 108700038897 Bcl-2 family Proteins 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 206010010356 Congenital anomaly Diseases 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 241000701959 Escherichia virus Lambda Species 0.000 description 2
• 102000002464 Galactosidases Human genes 0.000 description 2
• 108010093031 Galactosidases Proteins 0.000 description 2
• 102000005720 Glutathione transferase Human genes 0.000 description 2
• 108010070675 Glutathione transferase Proteins 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 208000037357 HIV infectious disease Diseases 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 108060003951 Immunoglobulin Proteins 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 108010000410 MSH receptor Proteins 0.000 description 2
• 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• 238000000636 Northern blotting Methods 0.000 description 2
• 206010030216 Oesophagitis Diseases 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 206010035742 Pneumonitis Diseases 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 206010038910 Retinitis Diseases 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 108090000253 Thyrotropin Receptors Proteins 0.000 description 2
• 102100029337 Thyrotropin receptor Human genes 0.000 description 2
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
• 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
• 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
• 102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 2
• 206010054094 Tumour necrosis Diseases 0.000 description 2
• 108020005202 Viral DNA Proteins 0.000 description 2
• 108700005077 Viral Genes Proteins 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 238000009825 accumulation Methods 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 230000009435 amidation Effects 0.000 description 2
• 238000007112 amidation reaction Methods 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 239000003816 antisense DNA Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000032823 cell division Effects 0.000 description 2
• 108091092328 cellular RNA Proteins 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 239000003184 complementary RNA Substances 0.000 description 2
• 238000009833 condensation Methods 0.000 description 2
• 230000005494 condensation Effects 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 239000003431 cross linking reagent Substances 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 239000000975 dye Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 208000006881 esophagitis Diseases 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 235000013861 fat-free Nutrition 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 238000009472 formulation Methods 0.000 description 2
• 238000013467 fragmentation Methods 0.000 description 2
• 238000006062 fragmentation reaction Methods 0.000 description 2
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
• 229960002963 ganciclovir Drugs 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 102000018358 immunoglobulin Human genes 0.000 description 2
• 229940072221 immunoglobulins Drugs 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 238000000302 molecular modelling Methods 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 230000002688 persistence Effects 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 2
• ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
• 238000000163 radioactive labelling Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 238000003345 scintillation counting Methods 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 238000003153 stable transfection Methods 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000009897 systematic effect Effects 0.000 description 2
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
• 238000010396 two-hybrid screening Methods 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
• ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
• RVWUFECBVNXJEN-YGOYTEALSA-N 1-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-prop-1-ynyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@@]1(C#CC)C[C@H](O)[C@@H](CO)O1 RVWUFECBVNXJEN-YGOYTEALSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
• XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 208000002109 Argyria Diseases 0.000 description 1
• 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• 241000700663 Avipoxvirus Species 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• NTTIDCCSYIDANP-UHFFFAOYSA-N BCCP Chemical compound BCCP NTTIDCCSYIDANP-UHFFFAOYSA-N 0.000 description 1
• 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 1
• 108700032588 Baculovirus p35 Proteins 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 1
• 101710180532 Biotin carboxyl carrier protein of acetyl-CoA carboxylase Proteins 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 102100032912 CD44 antigen Human genes 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 229940123169 Caspase inhibitor Drugs 0.000 description 1
• 206010057248 Cell death Diseases 0.000 description 1
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
• 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 102000001189 Cyclic Peptides Human genes 0.000 description 1
• 108010069514 Cyclic Peptides Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 102100024693 Death effector domain-containing protein Human genes 0.000 description 1
• 102000036292 Death effector domains Human genes 0.000 description 1
• 108091010866 Death effector domains Proteins 0.000 description 1
• 101710094581 Distal tail protein Proteins 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 241000725578 Equid gammaherpesvirus 2 Species 0.000 description 1
• 229920001917 Ficoll Polymers 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 108010001515 Galectin 4 Proteins 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 102000052874 Gastrin receptors Human genes 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
• 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
• 101000854890 Haemophilus phage HP1 (strain HP1c1) Probable terminase, ATPase subunit Proteins 0.000 description 1
• 101000768945 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 7.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 1
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101000830359 Homo sapiens Death effector domain-containing protein Proteins 0.000 description 1
• 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
• 241000598171 Human adenovirus sp. Species 0.000 description 1
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
• 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 208000000038 Hypoparathyroidism Diseases 0.000 description 1
• 101150027427 ICP4 gene Proteins 0.000 description 1
• 206010051645 Idiopathic neutropenia Diseases 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 206010022491 Insulin resistant diabetes Diseases 0.000 description 1
• 208000029523 Interstitial Lung disease Diseases 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 101000578717 Klebsiella pneumoniae Mannose-1-phosphate guanylyltransferase Proteins 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• 235000019766 L-Lysine Nutrition 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 101710192602 Latent membrane protein 1 Proteins 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 206010064912 Malignant transformation Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 102000014171 Milk Proteins Human genes 0.000 description 1
• 108010011756 Milk Proteins Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 102000009097 Phosphorylases Human genes 0.000 description 1
• 108010073135 Phosphorylases Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 108010002519 Prolactin Receptors Proteins 0.000 description 1
• 102100029000 Prolactin receptor Human genes 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108091034057 RNA (poly(A)) Proteins 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 241000701062 Saimiriine gammaherpesvirus 2 Species 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 101710109927 Tail assembly protein GT Proteins 0.000 description 1
• 235000019041 Teucrium polium Nutrition 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000002547 anomalous effect Effects 0.000 description 1
• 230000001093 anti-cancer Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000002529 anti-mitochondrial effect Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 230000034720 apoptotic signaling pathway Effects 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 238000010256 biochemical assay Methods 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229960002713 calcium chloride Drugs 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000036978 cell physiology Effects 0.000 description 1
• 108091092356 cellular DNA Proteins 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000003889 chemical engineering Methods 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
• 201000004709 chorioretinitis Diseases 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 239000012539 chromatography resin Substances 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 229960000724 cidofovir Drugs 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000013599 cloning vector Substances 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 231100000895 deafness Toxicity 0.000 description 1
• 230000005860 defense response to virus Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000009547 development abnormality Effects 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000006862 enzymatic digestion Effects 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 239000002360 explosive Substances 0.000 description 1
• 210000003722 extracellular fluid Anatomy 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 229960005102 foscarnet Drugs 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000005090 green fluorescent protein Substances 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 231100000086 high toxicity Toxicity 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 239000003667 hormone antagonist Substances 0.000 description 1
• 230000007446 host cell death Effects 0.000 description 1
• 230000009215 host defense mechanism Effects 0.000 description 1
• 102000053563 human MYC Human genes 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 235000018977 lysine Nutrition 0.000 description 1
• 230000002101 lytic effect Effects 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000036212 malign transformation Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• 238000007069 methylation reaction Methods 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 235000021239 milk protein Nutrition 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 239000005486 organic electrolyte Substances 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000007918 pathogenicity Effects 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 210000004896 polypeptide structure Anatomy 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000009819 post translational phosphorylation Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 229960002816 potassium chloride Drugs 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 206010036601 premature menopause Diseases 0.000 description 1
• 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 210000004129 prosencephalon Anatomy 0.000 description 1
• 230000018883 protein targeting Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229960004249 sodium acetate Drugs 0.000 description 1
• 229960002668 sodium chloride Drugs 0.000 description 1
• 239000001540 sodium lactate Substances 0.000 description 1
• 229940005581 sodium lactate Drugs 0.000 description 1
• 235000011088 sodium lactate Nutrition 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 229940035044 sorbitan monolaurate Drugs 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 230000030968 tissue homeostasis Effects 0.000 description 1
• 208000037816 tissue injury Diseases 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000017105 transposition Effects 0.000 description 1
• 229940117013 triethanolamine oleate Drugs 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1